Ludwig Catherine M, Hsiao Jennifer L, Lio Peter A, Shi Vivian Y
From the University of Illinois Chicago College of Medicine.
Division of Dermatology, Department of Medicine, University of California Los Angeles.
Dermatitis. 2021 Oct 1;32(1S):S4-S7. doi: 10.1097/DER.0000000000000690.
Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically-tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.
度普利尤单抗最近已获得美国食品药品监督管理局批准，用于治疗6至11岁儿童的中度至重度特应性皮炎。对于目前依赖免疫抑制剂（包括环孢素A、甲氨蝶呤和霉酚酸酯）的患者而言，它提供了一种安全性良好的新型治疗选择。特别是在当前的新冠疫情期间，应避免免疫抑制以保留内在抗病毒免疫力。向度普利尤单抗的转换应策略性地进行——逐渐减少免疫抑制剂用量，并通过与生物制剂重叠使用来将病情复发风险降至最低。在此，我们分别利用度普利尤单抗在12至18岁青少年和6至11岁儿童中的LIBERTY AD ADOL试验和LIBERTY AD PEDS试验的结果测量结果，提出一个为期8周的药物转换示意图。
